GAM Holding’s Alnylam Pharmaceuticals ALNY Stock Holding History

GAM Holding’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$361K	Hold	1,198	–	–	0.03%	238
2026 Q1	$396K	Buy	+1,198	New	+$408K	0.03%	238
2017 Q3	–	Sell	-10,000	Closed	-$798K	–	541
2017 Q2	$798K	Hold	10,000	–	–	0.01%	691
2017 Q1	$513K	Hold	10,000	–	–	0.01%	795
2016 Q4	$374K	Buy	10,000 +6,320	+172%	+$265K	0.01%	822
2016 Q3	$249K	Hold	3,680	–	–	﹤0.01%	864
2016 Q2	$204K	Buy	3,680 +1,391	+61%	+$87.6K	﹤0.01%	903
2016 Q1	$144K	Hold	2,289	–	–	﹤0.01%	901
2015 Q4	$215K	Buy	2,289 +810	+55%	+$75.1K	﹤0.01%	1001
2015 Q3	$119K	Hold	1,479	–	–	﹤0.01%	1052
2015 Q2	$177K	Buy	+1,479	New	+$177K	﹤0.01%	1020

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GAM Holding's ALNY Position: Q2 2026 in Review

GAM Holding held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 1,198 shares worth $361K. The position accounts for 0.03% of the portfolio, ranked #238.

GAM Holding first reported a position in ALNY in Q2 2015 and has held it in 11 quarters since. The position peaked at $798K in Q2 2017. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

GAM Holding held 1,198 shares of Alnylam Pharmaceuticals worth $361K as of Q2 2026.
GAM Holding left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up 0.03% of GAM Holding's portfolio in Q2 2026, its #238 holding.
GAM Holding first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 11 quarters since.
GAM Holding's Alnylam Pharmaceuticals position peaked at $798K in Q2 2017.
788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on GAM Holding's 13F filing for Q2 2026, filed 14 Aug 2026.